Altimmune aims to build Momentum in obesity
A readout in the next few weeks could put pemvidutide on course for blockbuster sales – or not.
Go or no go? Vaccines and neurology up for discussion
FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin.
Sanofi and Regeneron face a high-risk test for Dupixent
A pivotal readout approaches in COPD, where other biologicals have fallen short.
The next big tests for Argenx and its followers
Some believe that blocking FcRn has TNF-like potential, and J&J, Immunovant and UCB are all hot on Argenx’s heels.
Argenx's big bid to stay ahead
A crucial pivotal readout is approaching for the Belgian developer and Vyvgart, in a rare disease that represents the group’s riskiest move yet.
Go or no go? Overcoming delays
US Pdufa decisions loom for Apellis and Travere, while Menarini and Lilly got their approval firsts already.
Immuno-oncology goes subcutaneous
A pivotal study of Keytruda’s SC formulation is about to read out, but Roche could get to market first.
The first big test for the son of Enhertu
Readout of Tropion-Lung01, testing the most advanced indication for datopotamab, could lead to a first-half US filing.
Three Tigit players look to surprise in 2023
But two have already disappointed, and the third has shown little to suggest a positive outcome.
